{"id":"NCT00092443","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Dose Confirmation Efficacy Study (V260-007)","officialTitle":"Study of the Efficacy, Safety, and Immunogenicity of V260 at Expiry","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-09","primaryCompletion":"2004-06","completion":"2004-06","firstPosted":"2004-09-27","resultsPosted":"2009-07-10","lastUpdate":"2015-09-14"},"enrollment":1312,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Rotavirus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"RotaTeq™, rotavirus vaccine, live, oral, pentavalent","otherNames":["V260"]},{"type":"BIOLOGICAL","name":"Comparator: Placebo matching RotaTeq™","otherNames":[]}],"arms":[{"label":"RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)","type":"EXPERIMENTAL"},{"label":"Placebo matching RotaTeq™","type":"PLACEBO_COMPARATOR"}],"summary":"This study was designed to evaluate the safety of the investigational Rotavirus Vaccine and the efficacy to prevent Rotavirus Gastroenteritis.","primaryOutcome":{"measure":"Occurence of Clinical Rotavirus Disease Caused by the Composite of the Serotypes Contained Within the Vaccine More Than 14 Days Following the Third Dose.","timeFrame":"At least 14 days following the 3rd vaccination","effectByArm":[{"arm":"RotaTeq™ at Expiry Potency (≈1.1 x 107 IU/Dose)","deltaMin":15,"sd":null},{"arm":"Placebo Matching RotaTeq™","deltaMin":54,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["17200266"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":649},"commonTop":["Pyrexia","Irritability","Upper respiratory tract infection","Otitis media","Diarrhoea"]}}